Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
Almayali AAH, Boers M, Hartman L, Opris D, Bos R, Kok MR, Da Silva JA, Griep E, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Lems W, Smulders Y, Cutolo M, Ter Wee MM.
Almayali AAH, et al. Among authors: boers m.
Ann Rheum Dis. 2023 Oct;82(10):1307-1314. doi: 10.1136/ard-2023-223977. Epub 2023 Aug 4.
Ann Rheum Dis. 2023.
PMID: 37541762
Clinical Trial.